View Annual Report - Jules Stein Eye Institute
View Annual Report - Jules Stein Eye Institute
View Annual Report - Jules Stein Eye Institute
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Alejandra Young, PhD<br />
Debora B. Farber, PhD, DPhhc (Mentor)<br />
Interactions of the Melanosomal G-Protein-Coupled Receptor<br />
OA1 and Gai Proteins in the Retinal Pigment Epithelium<br />
Vision of Children Foundation<br />
Duration: 6/1/10–5/31/12 $222,757<br />
<strong>Eye</strong>STAR Graduate Student Grants<br />
Diana Katsman, MD, and Debora B. Farber, PhD, DPhhc<br />
Activation of Retinal Regenerative Potential by<br />
Embryonic Stem Cell-Derived Microvesicles<br />
Hope for Vision<br />
Duration: 1/15/10–1/14/12 $150,000<br />
Clinical Trials<br />
Lynn Gordon, M.D., Ph.D.<br />
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Weight-Reduction<br />
and/or Low Sodium Diet Plus Acetazolamide vs. Diet Plus Placebo I<br />
St. Luke’s College of Health Sciences<br />
Duration: 4/8/2010–1/31/12 $137,091<br />
A Phase 1 Open Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal<br />
Injection to Patients with Optic Nerve Atrophy<br />
Quark Pharmaceuticals<br />
Duration: 3/17/10–3/16/15 $248,024<br />
Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor”<br />
for Acute NAION<br />
ICON Clinical Research, Inc.<br />
Duration: 6/24/09–11/15/12 $43,580<br />
Jean-Pierre Hubschman, MD<br />
A Phase III, Multicenter, Randomized, Double-Masked Study Comparing<br />
the Efficacy and Safety of 0.5 mg and 2.0 mg of Ranibizumab<br />
Genentech<br />
Duration: 10/13/09–3/1/13 $845,625<br />
Steven D. Schwartz, MD<br />
Research with Retinal Cells Derived from Stem Cells for<br />
Stargardt Macular Dystrophy<br />
Advanced Cell Technology<br />
Duration: 3/23/11–3/22/13 $762,184<br />
Research with Retinal Cells Derived from Stem Cells for<br />
Age-Related Macular Degeneration<br />
Advanced Cell Technology<br />
Duration: 4/5/11–4/5/13 $835,693<br />
Applicator System in the Treatment of Patients with Diabetic Macular Edema<br />
Allergan Sales, LLC<br />
Duration: 8/25/05–12/31/13 $1,604,947<br />
Total awards for NIH, Clinical, and PI-Initiated Research include indirect cost.<br />
104 Appendices | Research Contracts and Grants